- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 340513, 6 pages
Comparison of Three Multiple Allergen Simultaneous Tests: RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy
Department of Laboratory Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul 110-744, Republic of Korea
Received 12 October 2012; Revised 14 November 2012; Accepted 19 November 2012
Academic Editor: Mina Hur
Copyright © 2013 Minje Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We compared the performances of 3 Multiple Allergen Simultaneous Test (MAST) assays: RIDA Allergy Screen (R-Biopharm, Darmstadt, Germany), MAST Optigen allergy system (Hitachi Chemical Diagnostics, Mountain View, CA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany). Forty sera that tested positive with the RIDA Allergy Screen (20 for food and 20 for inhalant panel) were subjected to MAST Optigen and Polycheck Allergy. For 26 available sera with discrepant results, 62 ImmunoCAP allergen-specific IgE tests (Pharmacia Diagnostics, Uppsala, Sweden) were performed. Percent agreements (kappa value) were 87.6% (0.59) and 91.3% (0.60) between RIDA and MAST; 89.9% (0.55) and 88.3% (0.46) between RIDA and Polycheck; and 86.8% (0.51) and 90.6% (0.61) between MAST and Polycheck. Compared with ImmunoCAP, agreements (kappa value) of inhalant and food panels were 51.7% (0.04) and 33.3% (−0.38) for RIDA; 60.7% (0.27) and 81.8% (0.59) for MAST; and 65.5% (0.26) and 45.5% (0.07) for Polycheck. The agreements between RIDA, MAST, and Polycheck and ImmunoCAP-positivity were 45.7%, 88.2%, and 28.6%, respectively, and the agreements for ImmunoCAP-negativity were 37.0%, 51.9%, and 88.9%. MAST Optigen showed better agreement with ImmunoCAP than other assays in the food panel. Better sensitivity of MAST Optigen and better specificity of Polycheck Allergy were suspected.
For the diagnosis of allergy, presence of allergen-specific immunoglobulin E (IgE) is usually established either by in vivo allergen skin tests or by in vitro allergen-specific IgE measurements [1, 2]. Although, in vivo skin test has been widely used to detect allergen-specific IgE. It is not a quantitative test and is difficult to be standardized . Therefore, detection of allergen-specific IgE is important for the diagnosis of allergy [1, 2]. Since the development and improvement of fluorescent enzyme immunoassay, the ImmunoCAP system (Pharmacia Diagnostics AB, Uppsala, Sweden) has been widely accepted as a reference method of allergen-specific IgE measurement because of its reliability, reproducibility, and good accordance with allergen skin test. However, individual ImmunoCAP test can only detect IgE against a single allergen, making it quite expensive to use in a clinical setting .
Therefore, several multiple allergen simultaneous tests (MAST) were developed, which can detect more than 30 allergen-specific IgE [5–8]. However, allergen-specific IgE assays are often modified as manufacturers improve allergens or change reagents to optimize test performance, affecting the diagnostic performance of those assays. MAST Optigen (Hitachi Chemical Diagnostics, Mountain View, CA, USA), upgraded version of MAST CLA (Hitachi Chemical Diagnostics, Mountain View, CA, USA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany) were recently introduced with good performances [6, 9, 10]. However, to the best of our knowledge, comparison of performances of those assays and analysis of concordance with ImmunoCAP system has not been performed. The aim of this study was to compare the performance of 3 MAST assays: RIDA Allergy Screen (R-Biopharm, Darmstadt, Germany), MAST Optigen allergy system (Hitachi Chemical Diagnostics, Mountain View, CA, USA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany) compared to ImmunoCAP system as a reference method.
2. Material and Methods
Forty sera that tested positive with the RIDA Allergy Screen (20 for the food panel and 20 for the inhalant panel) in immunology laboratory of Seoul National University Hospital from October to December 2010 were stored in −70°C until thawing for MAST Optigen and Polycheck Allergy assays. Allergens and classifications of results of three MAST assays are summarized in Table 1. Specific IgE assay with ImmunoCAP FEIA system (Phadia, Uppsala, Sweden) as a reference method was performed on 26 available residual sera out of 32 sera showing discrepant results (0 class in one assay and ≥2 class in another assay) among three MAST assays. The Institutional Review Board of Seoul National University Hospital approved this study (IRB no. 1-2011-0038).
2.2. RIDA Allergy Screen
Two hundred and fifty uL of patient serum were added to reaction wells of each of inhalant and food panels which contain 39 kinds of allergens. After 45 min of incubation at room temperature and wash, 250 uL of Biotin tagged anti-IgE were added. After 45 minutes of incubation at room temperature and wash, 250 uL of streptavidin conjugate were added. Twenty minutes of incubation at room temperature and wash, 250 uL of luminescent reagent were added. After 20 minutes of incubation, results were scanned with CCD camera (RIDA X-Screen Reader) and interpreted as class 0–6. Class ≥1 was interpreted as positive.
2.3. Polycheck Allergy
After washing of inhalant and food cassette which contain 39 kinds of allergens, 250 uL of start solution were added. After 60 seconds of incubation, 200 uL of patient sera were added. After 1 hour of incubation on shaker, 6 times of washes were performed. Anti-IgE was added and 45 minutes of incubation on shaker was performed. After 3 times of washes, 250 uL of enzyme tagged conjugate were added. After 20 minutes of incubation and washes, 250 uL of luminescent reagent were added. After 20 minutes of incubation, results were scanned and interpreted with Biocheck Image Software as class 0–6. Class ≥1 was interpreted as positive.
2.4. MAST Optigen
Patient sera were added to MASTpette chambers which contain 35 kinds of allergens. After 2 hours of incubation and washes, enzyme-tagged anti-IgE was added. After 2 hours of incubation and washes, luminescent reagent was added. After 10 minutes of incubation, results were interpreted as class 0–4 with MAST Optigen luminometer. Class ≥1 was interpreted as positive.
2.5. ImmunoCAP System Allergen-Specific IgE
All procedures were performed following the manufacture’s instruction. The detection range of ImmunoCAP FEIA was 0.1 to 100 kU/L. The sIgE classification scales were as follows: class 0: under 0.35 kU/L, class 1: 0.35–0.7 kU/L, class 2: 0.7–3.5 kU/L, class 3: 3.5–17.5 kU/L, class 4: 17.5–50 kU/L, class 5: 50–100 kU/L, class 6: over 100 kU/L. Class ≥1 was interpreted as positive.
2.6. Statistical Analysis
Agreement of detection results (Cohen’s kappa analysis) was analyzed. We assessed and categorized Kappa value as almost perfect (0.8–1.0), substantial (0.6–0.8), moderate (0.4–0.6), fair (0.2–0.4), and poor (below 0.2) . We calculated three different agreement percentages (positive, negative, and total agreement percentage). The positive and negative agreement percentages were calculated with the proportions of agreement for the average of their positive and negative responses. The total agreement percentage was calculated following: (total number of results − number of discrepancies) × 100/total number of results .
For each of the MAST inhalant and food panels, percent agreements (kappa value) were 87.6% (0.59) and 91.3% (0.60) between RIDA Allergy Screen and MAST Optigen; 89.9% (0.55) and 88.3% (0.46) between RIDA Allergy Screen and Polycheck Allergy; and 86.8% (0.51) and 90.6% (0.61) between MAST Optigen and Polycheck Allergy (Table 2).
Among the 20 sera tested by inhalant panel, for Housedust, most common inhalant allergen in Korean population , RIDA Allergy Screen was negative but MAST Optigen and Polycheck Allergy were positive on 4 sera (Table 3). Out of those 4 sera, 3 (with available residual sera) were tested by ImmunoCAP specific IgE. All of them showed positive results with ImmunoCAP (Table 4). Agreements of RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy with ImmunoCAP-positive results for House dust were 0% (0/3), 100% (3/3), and 100% (3/3), respectively (Table 4).
For Peach, three MAST assays showed highest number of discrepant sera (On 5 sera, MAST Optigen Screen was positive but and RIDA Allergy Screen and Polycheck Allergy were negative.) (Table 3). Three of them, tested by ImmunoCAP specific IgE, showed positive results. Agreements of Allergy Screen, MAST Optigen, and Polycheck Allergy with ImmunoCAP-positive results for Peach were 0% (0/3), 100% (3/3), and 0% (0/3), respectively (Table 4).
Compared with the 62 ImmunoCAP allergen-specific IgE test results for 26 discrepant sera, agreements (kappa value) of inhalant and food panels were 51.7% (0.04) and 33.3% (–0.38) for RIDA Allergy Screen; 60.7% (0.27) and 81.8% (0.59) for MAST Optigen; and 65.5% (0.26) and 45.5% (0.07) for Polycheck Allergy (Table 5). The agreements between RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy results and ImmunoCAP-positive results were 53.8%, 91.7%, and 30.8% for inhalant panel; 40.9%, 86.4%, and 27.3% for food panel, respectively (Table 5). The agreements between RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy results and ImmunoCAP-negative results were 50.0%, 37.5%, and 93.8% for inhalant panel; 18.2%, 72.7%, and 81.8% for food panel, respectively (Table 5).
Although, most of evaluations of performance of MAST assays were performed compared to allergen skin test [6, 13–16], comparisons with ImmunoCAP assay have been performed [5, 8, 17] considering the limitation of allergen skin test as a reference method due to the difference of principle of in vivo test from in vitro test . ImmunoCAP assay has been known to have established performance . Our study was also performed compared to ImmunoCAP assay.
In this study, 3 MAST assays showed moderate agreement (86.8–91.3%, kappa 0.46–0.61) among them (Table 2). In comparison with ImmunoCAP, three MAST assays showed similar agreements for Inhalant panel (51.7–65.5%, kappa 0.04–0.27), and MAST Optigen showed better agreement (81.8%, kappa 0.59) than Polycheck Allergy (45.5%, kappa 0.07) or RIDA Allergy Screen (33.3%, kappa −0.38) for food panel (Table 4). In previous reports, the agreement between RIDA Allergy Screen and ImmunoCAP has been reported as 29.1% (kappa −0.303) on 633 discrepant sera between RIDA Allergy Screen and another MAST assay, AdvanSure system (LG Life Science, Seoul, Korea) . Among 115 allergic patients, RIDA Allergy Screen showed 83.1% of agreement with ImmunoCAP for 10 common allergens . Our result is similar to former one  because we also performed ImmunoCAP assays only on sera with discrepant results among three MAST assays.
In our study, the agreement of MAST Optigen with ImmunoCAP-positive results was best (91.7% for inhalant panel and 86.4% for food panel) among 3 MAST assays (Table 5), implicating better sensitivity than other two assays. MAST CLA, previous version of MAST Optigen, has been reported to have slightly lower sensitivity (44.5%) than RIDA Allergy Screen (55.8%) or Polycheck Allergy (55.6%) . The performance of MAST Optigen might be improved compared to MAST CLA as previous report .
The agreement of Polycheck Allergy with ImmunoCAP-negative results was best (93.8% for inhalant panel and 81.8% for food panel) among 3 MAST assays, implicating better specificity than other two assays (Table 5). Polycheck Allergy has been reported to have similar specificity (93.5%) with an RIDA Allergy Screen (90.0%) or MAST CLA (96.0%) . In our study, ImmunoCAP assay was performed only on discrepant sera, which could make some different results from previous study .
For individual allergens, on House dust, which is most common allergen in Korean population  and on Peach, which showed most common discrepant results in our study, better sensitivities of MAST Optigen were suspected (Table 4). From previous study, when compared to allergen skin test, MAST CLA showed best performance on D. farinae . However, because of the retrospective design of our study, the small number of ImmunoCAP assay results due to shortage of residual sera is a limitation to see the performance of MAST assays on individual allergens. Further studies are needed on larger number of samples to compare the performance of MAST assays on individual allergens.
The 3 MAST assays: RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy showed moderate agreements among them. In comparison with ImmunoCAP allergen-specific IgE test, MAST Optigen showed better agreement than other assays in the food panel. Better sensitivity of MAST Optigen and better specificity of Polycheck Allergy were suspected. Further studies are needed in larger number of samples to know the performance of MAST assays for individual allergens.
M. Han and S. Shin share first authorship in this study.
Conflict of Interests
The authors declare that they have no conflict of interests.
- L. Cox, B. Williams, S. Sicherer et al., “Pearls and pitfalls of allergy diagnostic testing: report from the American College of Allergy, Asthma and Immunology/American Academy of Allergy, Asthma and Immunology Specific IgE Test Task Force,” Annals of Allergy, Asthma and Immunology, vol. 101, no. 6, pp. 580–592, 2008.
- P. Williams, W. A. C. Sewell, C. Bunn, R. Pumphrey, G. Read, and S. Jolles, “Clinical Immunology Review Series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy,” Clinical and Experimental Immunology, vol. 153, no. 1, pp. 10–18, 2008.
- D. R. Ownby, “Allergy testing: in vivo versus in vitro,” Pediatric Clinics of North America, vol. 35, no. 5, pp. 995–1009, 1988.
- M. Ollert, S. Weissenbacher, J. Rakoski, and J. Ring, “Allergen-specific IgE measured by a continuous random-access immunoanalyzer: interassay comparison and agreement with skin testing,” Clinical Chemistry, vol. 51, no. 7, pp. 1241–1249, 2005.
- J. H. Lee, K. H. Park, H. S. Kim, et al., “Specific IgE measurement using AdvanSure system: comparison of detection performance with ImmunoCAP system in Korean allergy patients,” Clinical Chimica Acta, vol. 413, no. 9-10, pp. 914–919, 2012.
- W. R. Jang, C. H. Nahm, J. H. Kim et al., “Allergen specific IgE measurement with polycheck allergy: comparison of three multiple allergen simultaneous tests,” Korean Journal of Laboratory Medicine, vol. 29, no. 5, pp. 465–472, 2009.
- S. E. Yang, H. B. Oh, S. J. Hong, D. H. Moon, and H. S. Chi, “Analysis of MAST Chemiluminescent Assay (MAST CLA) results performed in Asan Medical Center: suggestion for the improvement of MAST CLA performance,” The Korean Journal of Clinical Pathology, vol. 18, no. 4, pp. 660–666, 1998.
- E. J. Oh, S. A. Lee, J. Lim, Y. J. Park, K. Han, and Y. Kim, “Detection of allergen specific IgE by AdvanSure allergy screen test,” Korean Journal of Laboratory Medicine, vol. 30, no. 4, pp. 420–431, 2010.
- D. S. Park, J. H. Cho, K. E. Lee, et al., “Detection rate of allergen-specific IgE by multiple antigen simultanesou test-immunoblot assay,” The Korean Journal of Laboratory Medicine, vol. 24, no. 2, pp. 131–138, 2004.
- S. Lee, H. S. Lim, J. Park, and H. S. Kim, “A new automated multiple allergen simultaneous test-chemiluminescent assay (MAST-CLA) using an AP720S analyzer,” Clinica Chimica Acta, vol. 402, no. 1-2, pp. 182–188, 2009.
- J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical data,” Biometrics, vol. 33, no. 1, pp. 159–174, 1977.
- Clinical Laboratory Standards Institute, “Method comparison and bias estimation using patient samples,” Approved Guideline, vol. 22, no. 19, 2nd edition, 2008.
- A. Linneberg, L. L. N. Husemoen, N. H. Nielsen, F. Madsen, L. Frølund, and N. Johansen, “Screening for allergic respiratory disease in the general population with the ADVIA Centaur Allergy Screen Assay,” Allergy, vol. 61, no. 3, pp. 344–348, 2006.
- N. Ballardini, C. Nilsson, M. Nilsson, and G. Lilja, “ImmunoCAP™ Phadiatop® Infant—a new blood test for detecting IgE sensitisation in children at 2 years of age,” Allergy, vol. 61, no. 3, pp. 337–343, 2006.
- C. Contin-Bordes, A. Petersen, I. Chahine et al., “Comparison of ADVIA Centaur® and Pharmacia UniCAP® tests in the diagnosis of food allergy in children with atopic dermatitis,” Pediatric Allergy and Immunology, vol. 18, no. 7, pp. 614–620, 2007.
- C. M. Cobbaert and G. J. Jonker, “Allergy testing on the IMMULITE 2000 random-access immunoanalyzer—a clinical evaluation study,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 7, pp. 772–781, 2005.
- J. K. Kim, Y. M. Yoon, W. J. Jang, Y. J. Choi, S. C. Hong, and J. H. Cho, “Comparison study between MAST CLA and OPTIGEN,” American Journal of Rhinology and Allergy, vol. 25, no. 4, pp. e156–e159, 2011.